IP Library › Granted Patent US 12,428,636
Granted Patent B1
US 12,428,636 · App. 18/765,699 · Granted Sep 30, 2025

Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A

Inventors: David Gerhard Schwark (New Hill, NC); Joanne Hunt (Wake Forest, NC); Joseph Matthew Watts (Cary, NC)
Assignee: Pairwise Plants Services, Inc.
C12N15/102C07K19/00C12N9/22C12N9/78C12N15/111C07K2319/70C12N2310/20C12Y305/04001C12Y305/04002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,636
App. No.
18/765,699
Granted
Sep 30, 2025
Kind
B1
Abstract

This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.

Claims (49)

1. A method of modifying a target nucleic acid, comprising:

contacting the target nucleic acid with:

(a) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and at 595, and a guide nucleic acid,

(b) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and 542 and a valine at position 538, each of which position in the LbCas12a polypeptide of (a) and/or (b) is in reference to position numbering of the amino acid sequence of SEQ ID NO:180, and a guide nucleic acid,

wherein the LbCas12a polypeptide of (a) recognizes a PAM sequence in the target nucleic acid of

TTAA, TTAC, GTCT, ACTA, ACTC, ACTG, ATTA, ATTC, 

ATTG, CCTA, CCTC, CCTG, CTTA, CTTC, CTTG, GCTA, 

GCTC, GCTG, GTTA, GTTC, and/or GTTG,

 and the LbCas12a polypeptide of (b) recognizes a PAM sequence in the target nucleic acid of

AACC, TACC, AATC, GATA, AATA, AATG, GATG, and/or 

GATC,

 and/or

(c) a fusion protein and a guide nucleic acid, the fusion protein comprising (i) the LbCas12a polypeptide of (a) and (b), (ii) the LbCas12a polypeptide of (a) and a polypeptide of interest, or (iii) the LbCas12a polypeptide of (b) and a polypeptide of interest.

2. The method of claim 1 , wherein the LbCas12a polypeptide further comprises a mutation in the RuvC domain.

3. The method of claim 1 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase (deamination) activity, nickase activity, recombinase activity, transposase activity, methylase activity, glycosylase (DNA glycosylase) activity, glycosylase inhibitor activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, restriction endonuclease activity, nucleic acid binding activity, methyltransferase activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, polymerase activity, ligase activity, helicase activity, and/or photolyase activity.

4. The method of claim 3 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase activity, optionally wherein the at least one polypeptide or protein domain having deaminase activity is a cytosine deaminase domain or an adenine deaminase domain.

5. The method of claim 3 , wherein the polypeptide of interest has glycosylase inhibitor activity, optionally wherein the polypeptide of interest is a uracil-DNA glycosylase inhibitor (UGI).

6. A method of editing a target nucleic acid, comprising

contacting the target nucleic acid with:

(a) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and at 595, and a guide nucleic acid,

(b) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and 542 and a valine at position 538, each of which position in the LbCas12a polypeptide of (a) and/or (b) is in reference to position numbering of the amino acid sequence of SEQ ID NO:180, and a guide nucleic acid,

wherein the LbCas12a polypeptide of (a) recognizes a PAM sequence in the target nucleic acid of

TTAA, TTAC, GTCT, ACTA, ACTC, ACTG, ATTA, ATTC, 

ATTG, CCTA, CCTC, CCTG, CTTA, CTTC, CTTG, GCTA, 

GCTC, GCTG, GTTA, GTTC, and/or GTTG,

 and the LbCas12a polypeptide of (b) recognizes a PAM sequence in the target nucleic acid of

AACC, TACC, AATC, GATA, AATA, AATG, GATG, and/or 

GATC,

 and/or

(c) a fusion protein and a guide nucleic acid, the fusion protein comprising (i) the LbCas12a polypeptide of (a) and (b), (ii) the LbCas12a polypeptide of (a) and a polypeptide of interest, or (iii) the LbCas12a polypeptide of (b) and a polypeptide of interest;

thereby editing the target nucleic acid.

7. The method of claim 6 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase (deamination) activity, nickase activity, recombinase activity, transposase activity, methylase activity, glycosylase (DNA glycosylase) activity, glycosylase inhibitor activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, restriction endonuclease activity, nucleic acid binding activity, methyltransferase activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, polymerase activity, ligase activity, helicase activity, and/or photolyase activity.

8. The method of claim 7 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase activity, optionally, wherein the at least one polypeptide or protein domain having deaminase activity is a cytosine deaminase domain or an adenine deaminase domain.

9. The method of claim 7 , wherein the polypeptide of interest has glycosylase inhibitor activity, optionally wherein the polypeptide of interest is a uracil-DNA glycosylase inhibitor (UGI).

10. A method of editing a target nucleic acid, comprising contacting a cell or a cell free system comprising the target nucleic acid with:

(a) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and at 595, and a guide nucleic acid,

(b) a LbCas12a polypeptide having a mutation, wherein the mutation is an arginine at position 532 and 542 and a valine at position 538, each of which position in the LbCas12a polypeptide of (a) and/or (b) is in reference to position numbering of the amino acid sequence of SEQ ID NO:180, and a guide nucleic acid,

wherein the LbCas12a polypeptide of (a) recognizes a PAM sequence in the target nucleic acid of

TTAA, TTAC, GTCT, ACTA, ACTC, ACTG, ATTA, ATTC, 

ATTG, CCTA, CCTC, CCTG, CTTA, CTTC, CTTG, GCTA, 

GCTC, GCTG, GTTA, GTTC, and/or GTTG,

 and the LbCas12a polypeptide of (b) recognizes a PAM sequence in the target nucleic acid of

AACC, TACC, AATC, GATA, AATA, AATG, GATG, and/or

GATC,

 or an expression cassette or vector comprising the same and a guide nucleic acid, or an expression cassette or vector comprising the same; and/or

(c) a nucleic acid construct encoding a complex comprising a fusion protein and a guide nucleic acid, the fusion protein comprising (i) the LbCas12a polypeptide of (a) and (b), (ii) the LbCas12a polypeptide of (a) and a polypeptide of interest, or (iii) the LbCas12a polypeptide of (b) and a polypeptide of interest, or an expression cassette or vector comprising the same, thereby editing the target nucleic acid.

11. The method of claim 10 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase (deamination) activity, nickase activity, recombinase activity, transposase activity, methylase activity, glycosylase (DNA glycosylase) activity, glycosylase inhibitor activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, restriction endonuclease activity, nucleic acid binding activity, methyltransferase activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, polymerase activity, ligase activity, helicase activity, and/or photolyase activity.

12. The method of claim 11 , wherein the polypeptide of interest comprises at least one polypeptide or protein domain having deaminase activity, optionally, wherein the at least one polypeptide or protein domain having deaminase activity is a cytosine deaminase domain or an adenine deaminase domain.

13. The method of claim 11 , wherein the polypeptide of interest has glycosylase inhibitor activity, optionally wherein the polypeptide of interest is a uracil-DNA glycosylase inhibitor (UGI).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: SCHWARK, DAVID GERHARD; HUNT, JOANNE; WATTS, JOSEPH MATTHEW
To: PAIRWISE PLANTS SERVICES, INC.
Reel/Frame 068056/0889 →
References Cited (97)
US 5459252A · Conkling et al. · 1995 [cited by applicant]
US 5604121A · Hilder et al. · 1997 [cited by applicant]
US 5625136A · Koziel et al. · 1997 [cited by applicant]
US 5641876A · Mcelroy et al. · 1997 [cited by applicant]
US 6040504A · Rice et al. · 2000 [cited by applicant]
US 7141424B2 · Shin et al. · 2006 [cited by applicant]
US 7166770B2 · Hohn et al. · 2007 [cited by applicant]
US 7579516B2 · Boudreau · 2009 [cited by applicant]
US 9790490B2 · Zhang et al. · 2017 [cited by applicant]
US 9982053B2 · Pantaleo et al. · 2018 [cited by applicant]
US 10113163B2 · Liu et al. · 2018 [cited by applicant]
US 10167457B2 · Liu et al. · 2019 [cited by applicant]
US 10421972B2 · Lira et al. · 2019 [cited by applicant]
US 20170219596A1 · Tanenbaum et al. · 2017 [cited by applicant]
US 20180155716A1 · Zhang et al. · 2018 [cited by applicant]
US 20190010441A1 · Kindaichi · 2019 [cited by applicant]
US 20190010481A1 · Joung et al. · 2019 [cited by applicant]
US 20210115421A1 · Watts et al. · 2021 [cited by applicant]
US 20210155911A1 · Zhang · 2021 [cited by examiner]
US 20220112473A1 · Guffy et al. · 2022 [cited by applicant]
US 20220145305A1 · Petris et al. · 2022 [cited by applicant]
US 20230383271A1 · Guffy et al. · 2023 [cited by applicant]
US 20240076639A1 · Watts · 2024 [cited by applicant]
US 20240076640A1 · Jali · 2024 [cited by applicant]
US 20240141382A1 · Gasiunas · 2024 [cited by examiner]
US 20240229063A1 · Bauer · 2024 [cited by examiner]
CN 112725487A · 2021 [cited by examiner]
EP 0255378A2 · 1988 [cited by applicant]
EP 0342926A2 · 1989 [cited by applicant]
EP 0452269A2 · 1991 [cited by applicant]
WO 9307278A1 · 1993 [cited by applicant]
WO 9942587A1 · 1999 [cited by applicant]
WO 0173087A1 · 2001 [cited by applicant]
WO 2017184768A1 · 2017 [cited by applicant]
WO 2018136783A1 · 2018 [cited by applicant]
WO 2018176009A1 · 2018 [cited by applicant]
WO 2018213708A1 · 2018 [cited by applicant]
WO 2018213726A1 · 2018 [cited by applicant]
WO 2019126716A1 · 2019 [cited by applicant]
WO 2019126762A2 · 2019 [cited by applicant]
WO 2019138052A1 · 2019 [cited by applicant]
WO 2021016086A1 · 2021 [cited by applicant]
WO 2021076682A1 · 2021 [cited by applicant]
WO 2021087182A1 · 2021 [cited by applicant]
WO 2021222703A2 · 2021 [cited by applicant]
WO 2022047135A1 · 2022 [cited by applicant]
WO 2022174108A1 · 2022 [cited by applicant]
International Search Report and Written Opinion corresponding to PCT/US2019/055659; dated Mar. 9, 2021 (12 pages). [cited by applicant]
Gaj, Thomas, et al., “Genome-Editing Technologies: Principles and Applications”, Cold Spring Harbor Perspectives in Biology, 8:a023754, 2016. [cited by applicant]
Gao, Linyi, et al., “Engineered Cpf1 variants with altered PAM specificities”, Nat Biotechnol 35(8): 789-792, 2017. [cited by applicant]
Hu, Jonny H., et al., “Evolved Cas9 variants with broad PAM compatibility and high DNA specificity”, Nature 556: 57-63, 2018. [cited by applicant]
Jinek, Martin, et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity”, Science, 337(6096): 816-821, 2012. [cited by applicant]
Kleinstiver, Benjamin P., et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition”, Nat Biotechnol 33(12): 1293-1298, 2015. [cited by applicant]
Kleinstiver, Benjamin P., et al., “Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing”, Nat Biotechnol 37: 276-282, 2019. [cited by applicant]
Kleinstiver, Benjamin P., et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities”, Nature 523: 481-485, 2015. [cited by applicant]
Leenay, Ryan T., et al., “Identifying and Visualizing Functional PAM Diversity across CRISPR-Cas Systems”, Molecular Cell. 62: 137-147, 2016. [cited by applicant]
Nihongaki, et al., “A split CRISPR-Cpf1 platform for inducible genome editing and gene activation”, Nature Chemical Biology, 15: 882-888, 2019. [cited by applicant]
Nishimasu, Hiroshi, et al., “Engineered CRISPR-Cas9 nuclease with expanded targeting space”, Science 361 (6408): 1259-1262, 2018. [cited by applicant]
Tang, Xu, et al., “A CRISPR-Cpf1 system for efficient genome editing and transcriptional repression in plants”, Nat Plants 3, Article No. 17018, 2017. [cited by applicant]
Yamano, Takashi, et al., “Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1”, Molecular Cell, 67(4): 633-645.e3, 2017. [cited by applicant]
Zetsche, Bernd, et al., “Cpf1 is a single RNA-guided endonuclease of a Class 2 CRISPR-Cas system”, Cell. vol. 163(3): 759-771, 2015. [cited by applicant]
GenBank Accession No. 6KLB_D “Chain D, LbCas12a” (5 pages) (Sep. 17, 2019). [cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/US2021/047913 (25 pages) (mailed Jan. 27, 2022). [cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/US2023/063398 (21 pages) (mailed Jun. 29, 2023). [cited by applicant]
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in corresponding PCT Application No. PCT/US2024/018165 (Jun. 24, 2024). [cited by applicant]
Barrangou, Rodolphe , “Diversity of CRISPR-Cas immune systems and molecular machines”, Genome Biology, 16(247), 2015, 1-11. [cited by applicant]
Chen , et al., “Engineered DNase-inactive Cpf1 variants to improve targeting scope for base editing in [cited by applicant]
Deveau, Hélène , et al., “Phage Response to CRISPR-Encoded Resistance in Streptococcus thermophilus”, Journal of Bacteriology, 190(4), 2008, 1390-1400. [cited by applicant]
Esvelt, Kevin M., et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing”, Nature Methods, 10(11), 2013, 1116-1121. [cited by applicant]
Gaudelli, Nicole M., et al., “Programmable base editing of A.T to G.C in genomic DNA without DNA cleavage”, Nature. 551(7681), 2017, pp. 464-471. [cited by applicant]
Gilbreth, Ryan N., et al., “Structural insights for engineering binding proteins based on nonantibody scaffolds”, Current Opinion in Structural Biology, 22, 2012, 413-420. [cited by applicant]
Grissa , et al., “CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats”, Nucleic Acids Research, 35:W52-W57 (2007). [cited by applicant]
Hou , et al., “Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis”, Proceedings of the National Academy of Sciences, 110(39):15644-15649 (2013). [cited by applicant]
Huang, et al., “RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design”, PLoS ONE, 6(8):e24109 (2011). [cited by applicant]
Jablonska , et al., “Systematic classification of the His-Me finger superfamily”, Nucleic Acids Research, 45(20):11479-11494 (2017). [cited by applicant]
Jiang , et al., “CRISPR-assisted editing of bacterial genomes”, Nature Biotechnology, 31(3), 2013, 233-239. [cited by applicant]
Li, X. , et al., “Base editing with a Cpf1-cytidine deaminase fusion”, Nature Biotechnology, 36:324-327 2018. [cited by applicant]
Majorek , et al., “The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification”, Nucleic Acids Research, 42(7):4160-4179 (2014). [cited by applicant]
Mali , et al., “Cas9 as a versatile tool for engineering biology”, Nature Methods, 10(10), 2013, 957-963. [cited by applicant]
Mali, Prashant , et al., “RNA-Guided Human Genome Engineering via Cas9”, Science, 339(6121), 2013, 823-826. [cited by applicant]
Pediaditakis , et al., “ [cited by applicant]
Peng, et al., “Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4”, Proceedings of the National Academy of Sciences, 116(38):18928-18936 (2019). [cited by applicant]
Ran , et al., “Genome engineering using the CRISPR-Cas9 system”, Nature Protocols, 8(11):2281-2308 (2013). [cited by applicant]
Sadowski, M I, et al., “The sequence-structure relationship and protein function prediction”, Current Opinion in Structural Biology 19:357-362 (May 2009). [cited by applicant]
Schindele , et al., “Engineering CRISPR/LbCas12a for highly efficient, temperature-tolerant plant gene editing”. Plant Biotechnology Journal, 18:1118-1120 (2020). [cited by applicant]
Seffernick, Jennifer L., et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different”, Journal of Bacteriology, 183(8), 2001, 2405-2410. [cited by applicant]
Sha , et al., “Monobodies and other synthetic binding proteins for expanding protein science”, Protein Science, 26:910-924 (2017). [cited by applicant]
Singh , et al., “Protein Engineering Approaches in the Post-Genomic Era”, Current Protein & Peptide Science, 19:5-15 (2018). [cited by applicant]
Stella, et al., “Structure of the Cpf1 endonuclease R-loop complex after target DNA cleavage”, Nature, 546:559-563 (2017). [cited by applicant]
Swarts , et al., “Cas9 versus Cas12a/Cpf1: Structure-function comparisons and implications for genome editing”, WIREs RNA, 9(5):e1481 (2018). [cited by applicant]
Tak , et al., “Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors”, Nature Methods, 14(12):1163-1166 (2017). [cited by applicant]
Tang , et al., “Identification of Dehalobacter reductive dehalogenases that catalyse dechlorination of chloroform, 1, 1, 1-trichloroethane and 1,1-dichloroethane”, Philosophical Transactions of the Royal Society of Lond… [cited by applicant]
Thuronyi , et al., “Continuous evolution of base editors with expanded target compatibility and improved activity”, Nature Biotechnology, 37(9):1070-1079 (2019). [cited by applicant]
Vob , et al., “Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells”, Current Opinion in Chemical Biology, 28:194-201 (2015). [cited by applicant]
Witowski , et al., “Conversion of a B-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochemistry, 38:11643-11650 (1999). [cited by applicant]
Yamano, Takashi , et al., “Crystal structure of Cpf1 in complex with guide RNA and target DNA”, Cell, 165(4):949-962 (May 5, 2016). [cited by applicant]
U.S. Appl. No. 18/593,590, filed Mar. 1, 2024, Guffy et al. [cited by applicant]